Mannkind’s inhaled insulin showed promising results in its 26-week INHALE-1 pediatric study.
Results: inhaled insulin is just as effective as multiple daily injections (MDI) based on A1c results. Participants showed no concerns or differences in lung function.
Mannkind will meet with the FDA in early 2025 to discuss its submission for use in children. Ideally, Afrezza could be approved and available for use in children ages 4 to 17 years old by early 2026.
Learn more about it in these videos:
Using Inhaled Insulin with Type 1 Diabetes
https://lnkd.in/eiTeX6MT
How Fast is Inhaled Insulin
https://lnkd.in/eRMxVjV7
Getting Inhaled Insulin
https://lnkd.in/ed83Avnv
Ginger Vieira has lived with type 1 diabetes since 1999 along with a few other chronic illnesses! She is the Cofounder of the Diabetes Nerd Network and the Diabetes Nerd Marketing agency. Ginger has authored hundreds of articles and several books, including Exercise with Type 1 Diabetes, Pregnancy with Type 1 Diabetes, Dealing with Diabetes Burnout, and Stop Overeating During Lows. Over her 20-year career (so far) in diabetes, she’s produced hundreds of articles and videos about life with diabetes. Her background includes a Bachelor of Science in professional writing and certifications in coaching, personal training, powerlifting, and Ashtanga yoga.